Abstracts tagged "T cells and systemic lupus erythematosus (SLE)"

Abstract Number: 2499 • 2012 ACR/ARHP Annual Meeting
The Peroxisome-Proliferator Activated Receptor-γ Agonist Pioglitazone Modulates Aberrant T-Cell Responses in Systemic Lupus Erythematosus
Wenpu Zhao¹, Celine C. Berthier², Matthias Kretzler³ and Mariana J. Kaplan⁴, ¹University of Michigan Rheumatology, Ann Arbor, MI, ²Nephrology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁴Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Previous studies indicate that PPAR-γ agonists, including pioglitazone (PIO), down-regulate autoimmune responses and renal inflammation in murine SLE. However, the mechanisms implicated in this process…
Abstract Number: 2337 • 2012 ACR/ARHP Annual Meeting
Therapeutic Promotion of CD8 CTL by CpG Oligodeoxynucleotides (ODN) in an Induced Model of Lupus
Maksym Puliaiev¹, Kateryna Soloviova¹ and Charles S. Via², ¹Pathology Department, Uniformed Services University of Health Sciences, Bethesda, MD, ²Pathology Rm B3-100, Uniformed Services University of Health Sciences, Bethesda, MD
Background/Purpose: In addition to TcR signaling and costimulation, CD8 T cells require a third signal to mature into effector cytotoxic T lymphocytes (CTL). In pathogen…
Abstract Number: 2316 • 2012 ACR/ARHP Annual Meeting
Generation of CD4⁺ Follicular Helper Tcells by Complement and Immune Complexes
Anil K. Chauhan¹, Richard DiPaolo² and Terry L. Moore³, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Molecular Microbiology and Immunology, Saint Louis, MO, ³Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: Complement opsonized immune complexes (ICs) are key players of disease pathology. We showed in systemic lupus erythematosus (SLE), ICs and complement (C’) drive activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].